What is the appropriate treatment plan for a Black male with a recent drop in left ventricular ejection fraction (LVEF) from 50% to 41% over two months and a right ventricular outflow tract (RVOT) scar due to prior myocarditis?

Treatment Plan for Black Male with Declining LVEF (50% → 41%) and RVOT Scar from Prior Myocarditis

Initiate all four pillars of guideline-directed medical therapy immediately—SGLT2 inhibitor, beta-blocker, ARNI (or ACEi), and mineralocorticoid receptor antagonist—because this patient has heart failure with mildly reduced ejection fraction (HFmrEF, LVEF 41-49%) that warrants the same aggressive treatment as HFrEF, particularly given the rapid 2-month decline and the significantly worse prognosis documented in Black patients with recent-onset cardiomyopathy. 1, 2

Immediate Pharmacologic Intervention (Week 1-2)

Start All Four Foundational Medications Simultaneously

• SGLT2 inhibitor – Prescribe dapagliflozin 10 mg daily or empagliflozin 10 mg daily at full dose immediately; these agents reduce cardiovascular mortality and heart failure hospitalizations independent of diabetes status with minimal blood pressure effects. 1, 2

• Beta-blocker – Initiate carvedilol 3.125 mg twice daily, metoprolol succinate 12.5-25 mg daily, or bisoprolol 1.25 mg daily (provided resting heart rate > 50 bpm); beta-blockers confer mortality benefit in all patients with LVEF < 50% regardless of symptom status. 1, 2

• ARNI (preferred first-line) – Start sacubitril/valsartan 24/26 mg or 49/51 mg twice daily; post-hoc analyses demonstrate superior reduction in heart failure hospitalization and mortality even in the mildly reduced EF range compared to ACE inhibitors. If ARNI is not feasible due to cost or access, begin enalapril 2.5-5 mg twice daily or lisinopril 2.5-5 mg daily. 1, 2

• Mineralocorticoid receptor antagonist – Begin spironolactone 12.5-25 mg daily (or eplerenone 25 mg daily) if LVEF remains ≤35% on repeat imaging or if symptomatic (NYHA class II-IV); MRAs reduce mortality and sudden cardiac death with minimal blood pressure impact. Check baseline potassium and creatinine before initiation. 1, 2, 3

Critical Race-Specific Considerations

• Black race is independently associated with lower LVEF at follow-up in the IMAC-2 study of recent-onset cardiomyopathy, even after adjustment for baseline LVEF, sex, and blood pressure (p = 0.02). 4, 5

• Higher NYHA functional class and Black race were both associated with lower ejection fraction recovery in patients with non-ischemic cardiomyopathy, making aggressive early GDMT even more critical in this population. 4

• If the patient develops NYHA class III-IV symptoms, add hydralazine 37.5 mg three times daily plus isosorbide dinitrate 20 mg three times daily, titrating to hydralazine 75 mg TID and isosorbide dinitrate 40 mg TID; this combination provides additional mortality benefit specifically in self-identified African American patients. 4, 2

Up-Titration Strategy (Weeks 2-12)

• Increase one medication at a time every 1-2 weeks, selecting the class most likely to be tolerated based on heart rate and blood pressure. 2

• Target doses to achieve:

  • Sacubitril/valsartan 97/103 mg twice daily
  • Carvedilol 25-50 mg twice daily, metoprolol succinate 200 mg daily, or bisoprolol 10 mg daily
  • Spironolactone 25-50 mg daily (or eplerenone 50 mg daily)
  • SGLT2 inhibitor remains at full dose throughout 1, 2

• Before each dose increase, re-measure blood pressure and heart rate; after each MRA or ARNI/ACEi increase, re-check potassium and creatinine 1-2 weeks later. 2

Myocarditis-Specific Management

• Continue ACE inhibitors or ARNI indefinitely, even if LVEF normalizes above 50%; a study of 35 patients with acute myocarditis whose LVEF normalized showed that discontinuing ACE inhibitors led to significantly higher rates of recurrent heart failure with LVEF < 45% (33% vs 5%, p = 0.064) and lower follow-up ejection fraction (47% vs 57%, p = 0.002). 6

• The RVOT scar on cardiac MRI indicates myocardial fibrosis, which is associated with higher risk of mortality (HR 2.96) and sudden death (HR 4.61) in non-ischemic cardiomyopathy, independent of LVEF. 4

• Patients with myocarditis were specifically excluded from early ICD trials because of the potential for reversible cardiomyopathy, making the 3-6 month observation period on optimal medical therapy even more critical before device consideration. 4

Device Therapy Decision Algorithm

Do NOT implant an ICD now

• ICD is not indicated at LVEF 41%; primary prevention trials enrolled patients with LVEF ≤ 35%, and current guidelines require LVEF ≤ 35% despite ≥ 3 months of optimal medical therapy. 4

Re-evaluate LVEF at 3 months on optimal GDMT

• If LVEF remains ≤ 35% after 3 months of maximally tolerated GDMT, counsel the patient regarding ICD implantation for primary prevention of sudden cardiac death; the discussion should include the risk of sudden versus non-sudden death, efficacy, safety, and risks of ICD therapy. 4, 2

• If LVEF improves to > 40%, continue all four GDMT medications indefinitely because withdrawal is associated with relapse of ventricular dysfunction; 5.7% of patients in the DEFINITE trial had significant ventricular tachyarrhythmias even after ejection fraction improved to > 35%. 4, 1

• If LVEF declines further to ≤ 35%, proceed with ICD implantation after confirming expected survival > 1 year and absence of significant comorbidities limiting life expectancy. 4, 2

Monitoring Protocol

• Repeat transthoracic echocardiography at 3 months to assess LVEF trajectory and determine ICD eligibility; then repeat every 6-12 months to track ventricular remodeling. 1, 2

• Check serum potassium and creatinine 1-2 weeks after initiating or up-titrating MRA or ARNI, then monthly for 3 months, then every 3 months once stable on target doses. 2, 3

• Measure natriuretic peptides (BNP or NT-proBNP) at baseline to provide prognostic information and a reference for future therapy adjustments; repeat if clinical status changes. 1, 2

• Monitor blood pressure and heart rate at each visit; asymptomatic systolic BP 90-100 mmHg does not require dose reduction and should not delay GDMT optimization. 2, 7

• Schedule clinical follow-up every 3-6 months initially to assess symptom emergence, medication tolerance, blood pressure, renal function, and serum potassium. 1

Critical Prognostic Information

• The rapid 2-month decline from LVEF 50% to 41% is concerning; in a cohort of 322 HFpEF patients, 11.4% developed LVEF < 40% over median 37-month follow-up, and these patients had 5-fold higher mortality (adjusted HR 4.91) and 3.5-fold higher rates of death or HF hospitalization (adjusted HR 3.70). 8

• Smaller left ventricular end-diastolic diameter at presentation predicts better LVEF recovery (p < 0.0001 in IMAC-2), making baseline echocardiographic LV dimensions critical for prognostication. 4, 5

• HFmrEF (LVEF 41-49%) follows a dynamic trajectory; approximately 27% of patients decline to LVEF ≤ 40% while 45% improve to LVEF ≥ 50% over follow-up, underscoring the need for serial imaging and continuation of GDMT even if LVEF improves. 1

Common Pitfalls to Avoid

• Do not postpone GDMT awaiting symptom development or further LVEF decline; early treatment in asymptomatic or mildly symptomatic LV dysfunction reduces mortality and prevents progression to overt heart failure. 1, 2

• Do not discontinue GDMT if LVEF improves above 40% (termed HFimpEF); abrupt discontinuation is associated with relapse of LV dysfunction and clinical heart failure. 1, 2, 6

• Do not implant an ICD before 3 months of optimal medical therapy in myocarditis-related cardiomyopathy; early ICD placement did not impact survival in IMAC-2 subanalysis, and a significant proportion of patients demonstrate improvement in LV function with medical therapy alone. 4

• Do not rely on a single LVEF measurement for definitive therapeutic decisions; obtain two consecutive measurements to avoid misclassification due to measurement variability. 1